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cal response to short and long term treatment, based on all available randomized 
controlled trials (and indirect comparisons, where appropriate). All costs, in 2012 
Colombian pesos (1 USD$ = COP$1800) were obtained locally, using official databases 
for drug costs, and tariff manual (ISS 2001+30%) for procedures and complications. 
HAQ scores were used to calculate utilities, measured in QALYs. Annual discount 
rate was 3% both for cost outcomes. Results: Total costs, in million COP$, for the 
first year of treatment were $25.51 for adalimumab, $26.96 for certolizumab, $26.94 
for etanercept, $34.79 for golimumab, $25.63 for infliximab and $22.71 for tofacitinib. 
Tofacitinib represented a 16% cost reduction over a market-share weighted average 
of biological therapy in the first year, with equivalent or slightly better QALY gain 
(0.62 vs. 0.61). Cost savings and utility gained were maintained, and dominance was 
attained in more than 50% of Monte Carlo trials in the different time horizons and 
against all comparators considered. ConClusions: Under our model assumptions, 
and current costs in Colombia, for the national health care system, the sequence 
initiating with tofacitinib is a cost-saving alternative compared with biological 
therapy after failure to methotrexate in adults with rheumatoid arthritis, attaining 
at least the same average effectiveness in all the different time horizons considered.
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objeCtives: Rheumatoid Arthritis (RA) can be treated with TNFα inhibitors after the 
failure of conventional disease-modifying antirheumatic drugs like methotrexate. The 
percentage of German patients treated with TNFα inhibitors has been rising from 2 
% in 2000 to 20 % in 2008. In 2012, adalimumab was the most popular TNFα inhibitor 
and the best selling drug in the German statutory health insurance system with net 
expenditure of 581 mn € . We aim to analyze the cost-effectiveness of adalimumab for 
the treatment of RA in Germany. Methods: We set up a Markov Chain Monte Carlo 
lifetime model to simulate 10,000 hypothetical patients. Initially, patients can achieve 
one of three responses according to American College of Rheumatology criteria or 
fail the therapy. Each response is associated with an initial improvement in func-
tional status. In each cycle, treatment might be discontinued due to loss of efficacy 
or adverse events. Results: In the base case, patients gain 2.64 quality-adjusted 
life years (QALYs) with methotrexate monotherapy and 6.25 QALYs if adalimumab 
combination therapy is added to the treatment algorithm. The incremental cost-utility 
ratio (ICUR) is 32,210 € based on German list prices. After deduction of mandatory 
rebates and taxes, the ICUR is only 23,755 € . Adalimumab combination therapy low-
ers indirect cost from 295,070 € to 235,531 € . The ICUR based on total cost is 15,728 € 
(7,274 € after deducting taxes and rebates). ICURs further improve for younger baseline 
age. Limiting the simulation time to 5 or 10 years increases ICURs. ConClusions: 
Adalimumab therapy for the treatment of RA is cost-effective in Germany even in the 
base case scenario, which uses incorrectly high list prices and ignores indirect cost 
savings. Our analysis shows that cost-effectiveness analysis of drugs for chronic dis-
eases need to consider indirect costs and need to take a lifetime modeling perspective.
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objeCtives: Osteoarthritis commonly co-occurs with depression leading to poor 
health outcomes and high economic burden. The objective was to examine the con-
tributing factors to excess total health care expenditures associated with depres-
sion among those with osteoarthritis using a post-regression linear decomposition 
approach. Methods: Data were derived from the 2010 Medical Expenditure Panel 
Survey (MEPS) and self-reported osteoarthritis and depression were identified. Chi-
square tests and ordinary least square regressions (OLS) on log-transformed expen-
ditures were used to determine the association between depression status and 
health care expenditures after controlling for predisposing (gender, race, and age), 
enabling (marital status, education, employment, poverty status, insurance cover-
age, and usual source of care), need (perceived physical and mental health, anxi-
ety, presence of cardiovascular conditions, and other chronic conditions), lifestyle 
(Body-Mass index, exercise, and smoking status), and external environment factors 
(metro versus non-metro). Post-regression linear decomposition technique was used 
to estimate the relative contribution of individual-level variables to the excess expen-
ditures associated with depression and osteoarthritis compared to those without 
depression. Results: Among individuals with osteoarthritis 20.6% reported having 
depression. The average total health care expenditures were $13,684 for those with 
depression compared to $9,284 among those without depression. OLS regression on 
log-transformed total health care expenditures revealed that those with depression 
had 38.8% greater health care expenditures (p < 0.001) compared to adults without 
depression. Post-regression linear decomposition analysis indicated that nearly 50% 
of the difference in average health care expenditures among adults with and without 
depression can be explained by differences in individual-level characteristics between 
the two groups. These differences may be attributable mainly to the need factors 
such as perceived health status, anxiety, presence of cardiovascular conditions, and 
other chronic conditions. ConClusions: Results from the study suggest that excess 
health care expenditures associated with depression may be reduced by improving 
the co-management of chronic physical and mental health conditions.
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fracture incidence. For example, the published incidence_pop for spinal fractures 
for males age 80-84 is reported as 3.58/1,000 patient-years. When incidence_pop is 
used as incidence_no_risk, our model predicted 6.89 spinal fractures/1,000 patient-
years. After adjustment, the model predicted the fracture incidence accurately 
as 3.45/1,000 patient-years. ConClusions: The fracture incidence in non-risk 
patients, the baseline incidence used in the model, can be calculated using this 
method based on the fracture incidence from the study population, the risk factor 
prevalence, and the relative risk increase associated with the risk factor.
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objeCtives: Many patients with rheumatoid arthritis (RA) fail to respond ade-
quately to first-line therapy with conventional disease-modifying antirheumatic 
drugs (cDMARDs). Biologic disease-modifying antirheumatic drugs (bDMARDs) 
have improved outcomes, and multiple guidelines National Institute for Health 
and Care Excellence (NICE) govern their prescription in England and Wales. The 
study objective was to estimate the cost-effectiveness of treatment sequences of 
alternative bDMARDs versus cDMARDs in patients who have failed to respond to 
at least two cDMARDs. Methods: A discrete event simulation model was used 
to explore the cost-effectiveness of bDMARDs in combination with methotrexate 
versus cDMARDs. Populations of interest were patients with severe and moderate 
to severe RA who failed to respond to at least two cDMARDs including methotrex-
ate (cDMARD-IR). In the severe population, eight alternative bDMARD strategies 
and one cDMARD strategy were considered. In the moderate population, a single 
bDMARD strategy was compared against a cDMARD strategy. Strategies evaluated 
differed by the therapy with which the strategy began (a bDMARD or cDMARDs) 
and thereafter were based on current NICE guidance. The perspective was that of 
the UK National Health Service and Personal Social Services. The main outcome 
was the incremental cost-effectiveness ratio (ICER, expressed as cost per quality-
adjusted life years). Results: In a severe population, etanercept resulted in an 
ICER of £20,520 versus a cDMARD strategy (7 strategies strictly or extendedly domi-
nated). In a moderate to severe population the ICER for the etanercept strategy 
was £24,727 versus the cDMARD strategy. In probabilistic sensitivity analysis, the 
etanercept strategy had the highest probability of being cost-effective at a thresh-
old of £30,000. ConClusions: Based on the results of this analysis, a treatment 
strategy beginning with etanercept was considered to be the most cost-effective in 
patients with severe and moderate to severe RA who failed to respond to at least 
two conventional DMARDs.
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objeCtives: Following a recent price regulation for biopharmaceutical products 
in Colombia, we aimed to determine the impact on the cost of treatment with bio-
logic therapies for rheumatoid arthritis in patients who failed to respond to oral 
DMARDS. Methods: Current guidelines and evidence suggest similar efficacy and 
safety among 7 biologic products available in Colombia for the treatment of rheu-
matoid arthritis following DMARD failure: abatacept, adalimumab, certolizumab, 
etanercept, golimumab, infliximab and tocilizumab. We compared the annual direct 
medical cost of treatment (including drug costs, administration and monitoring) 
for intravenous (IV) and subcutaneous (SC) injections of these biologics. Dosages 
were determined based on the approved product labels and the average weight (62 
Kg) for a cohort of 275 patients with rheumatoid arthritis from a private institu-
tion in Bogota, Colombia. Costs were calculated using the data from most current 
price regulation guidance from the Ministry of Health (Circular 04-05/2013) and 
official sources for payments of treatments and procedures (SISMED). Sensitivity 
analyses were performed using different dosages and patients’ weights. Results: 
Direct annual cost of treatment with biologics was higher in the first year than in 
subsequent years, except for tocilizumab, etarnercept, adalimumab and golimumab 
which do not need additional dosages in the first year. Abatacept, both IV and SC, 
consistently showed the lowest direct medical cost after 3 years. The additional cost 
of treatment with other biologic therapies compared to abatacept ranged from 11% 
to 48% after 3 years. Despite having additional costs of administration, IV biologics 
had lower total direct medical cost compared to SC, mainly due to higher cost per 
dosage of the drugs. ConClusions: Under the current price regulation for biolog-
ics in Colombia, the cost of treatment for rheumatoid arthritis favors the use of 
abatacept as a first line biologic after DMARD failure.
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objeCtives: To compare, from the Colombian health care system perspective, both 
costs and effectiveness of tofacitinib with biological therapy as initial treatment in 
adults with rheumatoid arthritis after failure to methotrexate. Methods: We used 
an Excel-based patient level simulation model to compare, with different time hori-
zons (1, 2, 3 , 5, 10, and 20 years), cohorts of patients with tofacitinib as initial therapy 
compared with adalimumab, certolizumab, etanercept, golimumab or infliximab. 
All the patients modeled received concomitant treatment with methotrexate. The 
characteristics of the patients included: age, weight, initial HAQ score, and clini-
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and an annual knee X-ray, with 445 of them needing a knee brace during this period. 
During the study period there were 6,705 osteoarthritis-related hospitalizations, 
and over 10,000 combined physiotherapy(PT)/occupational therapy (OT) and home 
care nursing visits among patients prescribed HA. Hylan G-F 20 patients had fewer 
visits to a GP (36%) and specialist (39%), lower use of PT/OT (23% and 1%) and home 
care nursing (2%) services compared to other HA treatments (p< 0.05 for all com-
parisons). ConClusions: This analysis demonstrates that not all HA injections 
in patients with knee osteoarthritis represent similar resource utilization. Further 
real world examination of the effectiveness of HA for reducing clinical symptoms 
and improving health care resource utilization in knee osteoarthritis is warranted.
MuSCulAr-SkElEtAl diSordErS – Patient-reported outcomes & Patient 
Preference Studies
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objeCtives: The objective of this research report was to examine the relation-
ship between medication adherence levels and health care cost among patients 
with rheumatoid arthritis (RA). Methods: This study used a retrospective case 
comparison design to examine per member per month (PMPM) medical cost. The 
commercial population of patients with RA was extracted from two large claims 
data bases between years 2006 and 2009. The case cohort consisted of compliant 
patients (MPR ≥ 80%) receiving medication management from the Specialty divi-
sion of a large pharmacy retail chain. The comparison cohort consisted of non-
compliant patients (MPR < 80%) from a national benchmark pharmacy and medical 
claims data base. Using propensity scores, patients were matched on age, gender, 
risk score, socio-economic status, standard industrial classification code, comorbid 
conditions, and pre-medication gap. This process resulted in 512 one-to-one match 
pairs. Results: Patients with RA who were compliant to their medication regimen 
had 25% lower PMPM medical cost (in-patient, out-patient, professional, and emer-
gency room cost) than patients who were non-compliant ($637 vs. $855 respectively; 
P= 0.0458). The majority of this cost difference was due to in-patient cost which was 
46% lower for compliant patients, followed by professional cost which was 15% 
lower for compliant patients. A closer look at medical cost by levels of compliance 
reveals that PMPM medical cost decreased at each level of medication compliance 
described below. Patients with adherence levels less than 40% had PMPM cost of 
$1024, those with adherence levels between 40% and 80% had PMPM cost of $838, 
and patients with adherence levels greater than or equal to 80% had PMPM cost of 
$637. ConClusions: Medical cost decreases as adherence to the RA medication 
regimen increases. Given that the cost of treating RA can be extremely expensive, 
one approach to addressing this financial issue is to target medication adherence.
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objeCtives: The International Costs and Utilities Related to Osteoporotic fractures 
Study (ICUROS) is an ongoing 18 months prospective observational study with the 
objective of estimating resource use and health related quality of life related to osteo-
porotic fractures. This study aims to describe the resource utilization after vertebral 
fractures (sustained during 2007-2012) pooled from nine countries: Australia, Austria, 
France, Italy, Lithuania, Mexico, Russia, Spain, and the UK. Methods: Patients stud-
ied were ≥ 50 years and lived at home prior to fracture. Data were collected through 
patient interviews and review of medical records: at baseline, 4, 12, and 18 months after 
fracture. Only resource use related to the fracture event was collected. Results: There 
were 636, 572, and 536 patients available for analysis at 4, 12 and 18 months follow-up, 
respectively. The mean age (±SD) at fracture was 70±10 years and 81% were women. 
45% of patients were hospitalized. Mean hospital length of stay (LoS) (±SD) was 5.7±12.4 
days during months 0-4 and 0.9±9.8 during months 5-18. The mean number of physi-
cian visits (±SD) was 2.8±2.7 during months 0-4 and 1.9±3.4 between months 5-18. The 
mean number of nurse visits (±SD) was 1.4±8.5 and 1.5±19.9 during the corresponding 
periods, respectively. During months 0-4, 72% of patients used analgesics, 59% calcium/
vitamin D, and 41% pharmacological interventions for osteoporosis. The respective 
uptakes for months 5-18 were 56%, 55% and 34%. ConClusions: The majority of 
health care consumption related to vertebral fracture occurs during the first 4 months 
but substantial consumption persists up to 18 months after fracture.
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objeCtives: Musculoskeletal conditions are the primary cause of physical disability 
in the United States, and have implications for workplace productivity and employer 
health costs. This study determined the influence of employer-sponsored, onsite 
chiropractic care on health care utilization. Methods: A retrospective claims anal-
ysis of members of an employer-sponsored health plan receiving chiropractic care 
exclusively onsite or offsite from 2010-2012. Data were obtained from the employ-
er’s health benefits administration program. Eligible participants had continuous 
enrollment in the health plan and ≥ 1 billing code for chiropractic services during 
the 36-month study period. Utilization was assessed in 2 categories: radiological 
procedures and clinical care. Utilization differences were evaluated by having ≥ 1 
health care event in any category. Continuous variables were summarized as means, 
and binary variables as counts and proportions. Differences were assessed via chi-
square test for categorical variables and t-test and Kruskal-Wallis non-parametric 
test for continuous variables. Comparisons were considered significant at alpha = 
0.05. Results: The analysis included 876 onsite and 759 offsite participants. The 
populations were similar in gender; the onsite group was slightly younger. The 
offsite group received more radiology services overall (55.5% vs 38.2%, P< 0.001) 
including x-ray (46.0% vs 26.6%; P < 0.0001); ultrasound (15.8% vs 10.7%, P< 0.0001), 
and magnetic resonance imaging (14.6% vs 12.4%, P< 0.0001); had higher outpatient 
(47.3% vs 30.2%, P< 0.0001) and emergency department (19.0% vs 13.1%; P = 0.022) uti-
lization; and demonstrated greater use of chiropractic care (mean 15.2 vs 9.16 visits; 
P< 0.0001) and physical therapy (mean 9.6 vs 1.5 visits; P< 0.0001). ConClusions: 
In patients needing chiropractic care, those utilizing onsite services had lower 
health care utilization, including radiology services , clinical care, and counts of 
chiropractic and physical therapy services. The study results support the value of 
chiropractic services offered at onsite health centers, where more tightly managed 
and evidence-based approaches to musculoskeletal conditions can be facilitated.
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objeCtives: To examine the health care resource utilization in patients with knee 
osteoarthritis and treated with Hylan G-F 20 (Synvisc, Genzyme Biosurgery) com-
pared with patients treated with alternative intra-articular hyaluronic acid (HA) 
injections in Ontario, Canada. Methods: This is an observational, prospective 
cohort of patients 18 years and older who, between June 1, 1999 and December 31, 
2012 had: 1) a diagnosis of knee osteoarthritis identified by ICD 9-10 or text coding; 2) 
received at least 1 treatment cycle with intra-articular HA and; 3) complete pain and 
mobility data for each treatment cycle. Data from the Southwestern Ontario (SWO) 
database, has been continuously compiled since 1999 and includes demographic, 
biometric, laboratory, diagnostic and health resource measures as collected in a 
primary care setting. Health care resource utilization included clinic visits, emer-
gency visits, hospitalizations, home care visits, knee bracing, radiographs, and work 
absenteeism. Differences between treatments were compared using independent 
sample t-tests. Results: 6,618 patients met all inclusion criteria of which 44% 
were treated with Hylan G-F 20. Patients were similar across treatment groups. 
During the follow-up period, patients received, on average, 6 HA treatment cycles 
